KAMADA » INVESTORS » NEWS & EVENTS

NEWS & EVENTS

Latest News

Kamada Announces Interim Results from Phase 2 Clinical Trial of Intravenous Alpha-1 Antitrypsin Treatment for Prevention of Lung Transplant Rejection

Jan. 8, 2018

The company announced interim results from the Company’s Phase 2 trial of intravenous Alpha-1 Antitrypsin (IV AAT) for the prevention of lung transplant rejection.

Kamada Announces Collaboration with a Consortium of Prominent Hospitals led by The Mount Sinai Hospital to Evaluate its Alpha-1 Antitrypsin Product for Preemption of Steroid Refractory Acute Graft-versus-Host Disease

Jan. 4, 2018

Kamada announced a collaboration with the Mount Sinai Acute GvHD International Consortium (MAGIC) to conduct a proof-of-concept clinical trial assessing the safety and preliminary efficacy of Kamada’s Alpha- 1-Antitrypsin (AAT) as preemptive therapy for patients at high-risk for the development of steroidrefractory acute GvHD (SR-aGvHD).


Upcoming Events

Kamada to participate in 36TH ANNUAL HEALTHCARE CONFERENCE (J.P.Morgan)

Jan. 8-11, 2018 / San Francisco, California

The J.P. Morgan Healthcare Conference continues their tradition of hosting the largest and most informative healthcare investment symposium in the industry. The conference provides a unique opportunity for investors to visit with so many inter-related industry leaders in one setting.


Past Event

Kamada to participate in 59th ASH Annual Meeting & Exposition

Dec. 9-12, 2017 / Atlanta, GA

The meeting will provide an invaluable educational experience and the opportunity to review thousands of scientific abstracts highlighting updates in the hottest topics in hematology. Network with top minds in the field and a global community of more than 25,000 hematology professionals from every subspecialty.